**4441** Springdale Road
Louisville, KY 40241
Phone 502 -815-8000
Fax 502-815-8001
usworldmeds.com

Date: February 13, 2024

Via Email: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. § 4637

To Whom It May Concern:

On January 18, 2024, and pursuant to 18 V.S.A. § 4637(b), USWM, LLC submitted a new drug introduction notice for the following (the "Product"):

| NDC | Product Description | WAC |
|---|---|---|
| 78670-0150-01 | IWILFIN Tablets 192MG, 100 ct | $9,000.00 |

USWM, LLC now provides the following additional information pursuant to 18 V.S.A. § 4637(c).

**1. US and international marketing and pricing plans used at launch:** In establishing the pricing for its prescription drugs, our organization considers various factors, including, without limitation, the competitive landscape and pricing conditions, manufacturing and supply considerations, profitability, research and development costs, therapeutic class and patient population, distribution channels, and insurance coverage. Moreover, the pricing decision-making process considers contracts, customer relationships, public policy, legal considerations, and the needs of institutional purchasers.

**2. Estimated volume of patients:** Average number of patients are 550 a month.

**3. Whether the FDA granted breakthrough therapy designation or priority review:** Yes, FDA has granted this product as a breakthrough therapy and provided a priority review.

**4. Date and price of acquisition: N/A**

Thank you for your consideration.

Sincerely,
Pam Sheehan
Controller,
USWM, LLC